Immunology

Immunology covers primary immunodeficiency diseases — inherited or acquired defects in the immune system's ability to defend against infection, regulate inflammation, or prevent autoimmunity.


About Primary Immunodeficiency Diseases

Primary immunodeficiency diseases (PIDs) are a group of more than 450 distinct genetic disorders in which one or more components of the immune system fail to function correctly. They differ fundamentally from secondary immunodeficiencies (caused by HIV, chemotherapy, or malnutrition) in that the defect is inherited — present from birth in the genome, even if symptoms do not appear until later in childhood or adulthood.

PIDs span a wide spectrum of severity, from selective IgA deficiency (affecting 1 in 500 people, often without symptoms) to severe combined immunodeficiency (SCID), which is incompatible with normal life without stem cell transplantation. What unites them is that the immune system's ability to do one or more of its core jobs — recognizing pathogens, killing bacteria and fungi, clearing viruses, regulating inflammation, or distinguishing self from non-self — is impaired.

The Five Arms of Immunity and Their Defects

Understanding which arm of immunity is affected tells you almost everything about which infections a patient will suffer:

The Diagnostic Delay Problem

The average time from first symptoms to confirmed PID diagnosis is 10–15 years for many conditions. This delay causes preventable organ damage — bronchiectasis, neurological deterioration, liver disease — that could be minimized with early diagnosis and treatment. The Jeffrey Modell Foundation's "10 Warning Signs of Primary Immunodeficiency" has been widely distributed to raise awareness among both patients and primary care physicians.

Treatment Principles

Treatment depends on the specific defect. Antibody deficiencies are treated with immunoglobulin replacement therapy (IVIG or SCIG), which provides passive protection against the infections the patient cannot prevent. SCID and some cases of Wiskott-Aldrich Syndrome are treated with hematopoietic stem cell transplantation (HSCT), which can be curative. DOCK8-deficient AR-HIES responds particularly well to HSCT. Newer treatments include gene therapy (approved for ADA-SCID) and targeted small-molecule therapies for specific genetic defects.


Connections